Anti-Infective Agents Market Size is Projected to Reach US$ 195.8 Billion by 2035 With a CAGR of 2.6% | Fact.MR

The anti-infective agents market size is estimated at USD 151 billion in 2025. According to Fact.MR analysis, the market for anti-infective agents will rise at a CAGR of 2.6% during the forecast period and reach USD 195.8 billion in 2035.

The steady increase in antimicrobial resistance, combined with a growing infectious disease burden across the globe, is serving as a key driver for long-term demand. Besides that, growing government and private investment in developing antibiotics, particularly in emerging and developing economies, is promoting sustainable development in the global pharma sector.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8045

Market Analysis

The industry is developing steadily, driven by worldwide AMR needs, ramped-up R&D spendings, and high-priority anti-infectives regulation by authorities. Regional players and pharma innovators benefit, with low-margin generics threatened by escalating price and compliance pressure.

Country-wise Analysis

The U.S. market for anti-infective agents will expand at a 6.8% CAGR over the forecast period. The widespread incidence of infectious diseases, global prevalence of antimicrobial resistance, and ongoing demand for new anti-infective therapy propel growth. The U.S. pharma industry has one of the most sophisticated pharma environments in terms of high R&D investment.

The UK anti-infective agents market will have a 5.9% CAGR over the study period. Government-supported surveillance programs and infection control strategies are the backbone of the UK anti-infective agents market growth.

The German anti-infective agents market will witness a growth at 6.0% CAGR over the study period. A well-established healthcare infrastructure, robust healthcare spending, and robust pharmaceutical R&D capabilities fuel the growth.

The Chinese market for anti-infective agents is predicted to rise at 7.4% CAGR over the forecast period. China is experiencing accelerated healthcare evolution with government investment, urbanization, and increasing middle-class demographics with access to quality healthcare. The nation has stepped up nationwide campaigns against the abuse of antibiotics and the sale of antibiotics over the counter, with stricter regulatory oversight of anti-infective drug distribution.

Segment-wise Analsysis

By Type :

By 2025, the market for anti-infective agents will be led by the antiviral segment, which will hold the largest 51% market share compared to antibacterial agents' 30%. Evidently, the trend reflects the global world's healthcare priorities as viral threats persistently emerge and re-emerge, impacting public health systems.

By Range :

By type, broad-spectrum agents dominate the market for anti-infective agents with a 60% market share compared to the other 40% market share of narrow-spectrum agents. This pattern confirms the ongoing preference by clinicians towards therapeutics, which provides broad activity against a spectrum of pathogens, particularly when in the context of acute and empiric treatment.

Competitive Outlook

Anti-infective agents market is extensive and competitive where global pharmaceuticals giants are betting on broad-spectrum antibiotics together with antiviral and antifungal therapeutics. Large R&D pipeline, regulatory milestones, and symbiotic strategic collaborative partnerships with biotech firms, the major stalwarts are GlaxoSmithKline, Pfizer, and Bayer AG.

Sanofi, Merck Co. and Bristol-Myers Squibb form a robust industry presence with future-generation anti-infectives, such as combination therapies that employ new mechanisms targeting resistant pathogens. These firms are enhancing their drug portfolios through strategic acquisitions and licensing deals, expanding their portfolios in infectious disease treatment.

Abbott, Novartis, and Johnson and Johnson have actually concentrated their investments in antiviral innovation, such as creating therapies for HIV and hepatitis C, and expanded their penetration across the globe by partnering with public health entities and governments in expanding access to their critical medicines, as well as better investment in developing diagnostics, vaccines, and precision medicine strategies. These heightened cases of incurability of multi-drug-resistant infection have prompted these firms to invest more in rapid diagnostics, vaccines, and precision medicine strategies.

Browse Full Report: https://www.factmr.com/report/anti-infective-agents-market

Key Players

GlaxoSmithKline plc.
Pfizer Inc.
Bayer AG
Sanofi
Merck & Co., Inc.
Bristol-Myers Squibb Company
Abbott
Novartis AG
Johnson & Johnson Services Inc.
Gilead Sciences, Inc.
Astellas Pharma Inc.
Segmentation

By Type :
Antiviral
Antibacterial
Antifungal
Others
By Range :
Narrow Spectrum
Broad Spectrum
By Route of Administration :
IV
Oral
Topical
Others
By Indication :
HIV
Tuberculosis
Respiratory Infection
Pneumonia
Others
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
E-Commerce
Others
By Region :
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)
Check out More Related Studies Published by Fact.MR:

Breathalyzer Market
https://www.factmr.com/report/125/breathalyzer-market

Radiotherapy Devices Market
https://www.factmr.com/report/77/radiotherapy-devices-market

Cardiac POC Testing Devices Market
https://www.factmr.com/report/cardiac-poc-testing-devices-market

Kidney Dialysis Equipment and Supplies Market
https://www.factmr.com/report/kidney-dialysis-equipment-and-supplies-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.